酶免检测双试剂反应性核酸初筛无反应性献血者核酸重复检测结果分析

臧亮 ,  周磊 ,  刘笑春 ,  孙鹏 ,  范亚欣 ,  梁晓华

中国输血杂志 ›› 2026, Vol. 39 ›› Issue (6) : 757 -761.

PDF (1110KB)
中国输血杂志 ›› 2026, Vol. 39 ›› Issue (6) : 757 -761. DOI: 10.13303/j.cjbt.issn.1004-549x.2026.06.008
论著

酶免检测双试剂反应性核酸初筛无反应性献血者核酸重复检测结果分析

作者信息 +

Analysis of repeated nucleic acid test results in blood donors with dual-reactive enzyme-linked immunosorbent assay results and nonreactive nucleic acid test results

Author information +
文章历史 +
PDF (1136K)

摘要

目的 通过分析酶免检测(ELISA)双试剂反应性核酸检测(NAT)初筛无反应性献血者的标本的 NAT 重复检测结果,探讨实验室现有检测模式和检测策略对血液安全的影响。方法 收集 2017-2025 年大连市血液中心 ELISA 检测双试剂反应性 NAT 初筛检测无反应性的献血者标本,采用转录介导扩增(TMA)及聚合酶链反应(PCR) 2 个系统进行 NAT 重复检测,结合 NAT 重复检测结果的出现次数及检测模式(混检与单检)进行比较分析。结果 共纳入 ELISA 检测双试剂反应性 NAT 初筛无反应性标本 199 份,其中 HBsAg ELISA 反应性标本 66 份、抗-HCV ELISA 反应性标本 130 份、HIV Ag/ Ab ELISA 反应性标本 3 份。 HBsAg ELISA 反应性标本中,57 份(57/ 66,86. 4%)在 NAT 重复检测中至少出现 1 次反应性结果,其中 49 份可重复检出≥2 次。 HBcAb ECA 反应性标本 64 份(64/ 66, 97. 0%),无反应性2 份(2/ 66,3. 0%),2 份 HBcAb ECA 无反应性标本在 NAT 重复检测中均未检出反应性结果。 抗-HCV 和 HIV Ag/ Ab ELISA 反应性标本未观察到 NAT 的重复检出。 TMA 检测系统经 3 次联检和 1 次鉴别检测共检出反应性标本 50 份(50/ 66,75. 8%);PCR 检测系统经 4 次单检共检出反应性标本 51 份(51/ 66,77. 3%)。 2 个检测系统均检出反应性标本 44 份,仅 TMA 检测系统检出反应性标本 6 份,仅 PCR 检测系统检出反应性标本 7 份。结论 在 ELISA 双试剂反应性 NAT 初筛无反应性的献血者标本中,HBsAg ELISA 反应性标本存在较高比例的低病毒载量感染,HBV DNA 检出呈间歇性及概率性特征。 NAT 次数及检测策略对低病毒载量标本的识别具有重要影响。 应充分认识 HBV 低病毒载量感染标本的检测特点,以优化血液筛查策略并提高血液安全性。

Abstract

Objective To investigate the impact of current laboratory testing models and screening strategies on blood safety by analyzing repeat nucleic acid testing (NAT) results obtained from blood donors who had dual-reactive enzyme-linked immunosorbent assay (ELISA) results but were initially nonreactive by NAT. Methods Samples from blood donors with dual-reactive ELISA results and initially nonreactive NAT results collected at Dalian Blood Center from 2017 to 2025 were included. Repeated testing was performed using two NAT systems:transcription-mediated amplification (TMA) and polymerase chain reaction (PCR). The results were analyzed in terms of the frequency of reactive NAT results and the tes-ting strategies, including minipool and individual donation testing. Results A total of 199 samples with dual-reactive ELISA results and initially nonreactive NAT results were included, comprising 66 HBsAg-reactive samples, 130 anti-HCV-reactive samples, and 3 HIV Ag/ Ab-reactive samples. Among the HBsAg-reactive samples, 57 (57/ 66, 86. 4%) showed at least one reactive NAT result upon repeated testing, and 49 showed two or more repeat reactive results. Anti-HBc was re-active in 64 samples (64/ 66, 97. 0%) and nonreactive in 2 samples (2/ 66, 3. 0%); both anti-HBc-nonreactive samples remained nonreactive in repeated NAT. No stable repeat nucleic acid reactivity was observed in anti-HCV-or HIV Ag/ Ab-reactive samples. The TMA system detected 50 reactive samples (50/ 66, 75. 8%) through three combined assays plus one discriminatory assay, whereas the PCR system detected 51 reactive samples (51/ 66, 77. 3%) through four rounds of indi-vidual-donation testing. Fortyfour samples were reactive on both systems, 6 were reactive only on the TMA system, and 7 were reactive only on the PCR system. Conclusion Among blood donors with dual-reactive ELISA results and initially non-reactive NAT results, HBsAg-reactive samples contain a high proportion of low viral load HBV-related cases, with intermit-tent and probabilistic nucleic acid detectability. Both testing frequency and detection strategy significantly affect the detec-tion of low viral load samples. These findings highlight the importance of recognizing the detection characteristics of low viral load HBV-related samples in order to optimize blood screening strategies and improve blood safety.

关键词

血液筛查 / 核酸检测 / 酶免检测 / 重复检测

Key words

blood screening / nucleic acid testing / enzyme-linked immunosorbent assay / repeat testing

引用本文

引用格式 ▾
臧亮,周磊,刘笑春,孙鹏,范亚欣,梁晓华. 酶免检测双试剂反应性核酸初筛无反应性献血者核酸重复检测结果分析[J]. 中国输血杂志, 2026, 39(6): 757-761 DOI:10.13303/j.cjbt.issn.1004-549x.2026.06.008

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

ROTH W K. Hepatitis B and blood transfusion[J].Infus Ther Transfus Med,2007,34(1):20-24.

[2]

CANDOTTI D,ALLAIN J P. Transfusion-transmitted hepatitis B virus infection[J].J Hepatol,2009,51(4):798-809.

[3]

RAIMONDO G,ALLAIN J P,BRUNETTO M R,et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection[J].J Hepatol,2008,49(4):652-657.

[4]

景媛媛,段勇,刘雅东,等. 2012-2021 年西安地区无偿献血者血液筛查结果的回顾性研究[J].中国输血杂志,2023,35(6):533-538.

[5]

JING Y Y, DUAN Y, LIU Y D, et al. A retrospective study of blood screening results among voluntary blood donors in Xi’ an from 2012 to 2021[J].Chin J Blood Transfusion, 2023,35(6):533-538.

[6]

ALLAIN J P. Occult hepatitis B virus infection:implications in transfusion[J].Vox Sang,2004,86(2):83-91.

[7]

KIELY P,MARGARITIS A R,SEED C R,et al. Hepatitis B virus nucleic acid amplification testing of Australian blood donors highlights the complexity of confirming occult hepatitis B virus infection[J].Transfusion,2014,54(8):2084-2091.

[8]

ALTER M J . Epidemiology of hepatitis C virus infection[J].World J Gastroenterol, 2007,13(17):2436-2441.

[9]

KLEINMAN S H,LELIE N,BUSCH M P . Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion[J].Transfusion,2009,49(11):2454-2489.

[10]

BRANSON B M,OWEN S M,WESOLOWSKI L G,et al. Laboratory testing for the diagnosis of HIV infection:up-dated recommendations[R]. Atlanta:Centers for Disease Control and Prevention,2014.

[11]

GERLICH W H. Medical virology of hepatitis B:how it began and where we are now[J].Virol J,2013,10(1):239-264.

[12]

TU T,BUDZINSKA M A,SHACKEL N A,et al. HBV DNA integration:molecular mechanisms and clinical im-plications[J].Viruses,2017,9(4):75-93.

[13]

REVILL P A,CHISARI F V,BLOCK J M,et al. A glob-al scientific strategy to cure hepatitis B[J].Lancet Gas-troenterol Hepatol,2019,4(7):545-558.

[14]

BRUSS V. Hepatitis B virus morphogenesis[J].World J Gastroenterol,2007,13(1): 65-73.

[15]

GERLICH W H,BREMER C,SANIEWSKI M,et al. Oc-cult hepatitis B virus infection: detection and signifi-cance[J].Dig Dis,2010,28(1):116-125.

[16]

侯云,冯秋霞,李蓓,等. 改进核酸筛查混检阳性池再检模式的探讨[J].中国输血杂志, 2024,37(2):190-195.

[17]

HOU Y,FENG Q X,LI B,et al. Discussion on improving the retesting mode for minipool NAT-positive samples in blood screening[J].Chin J Blood Transfusion,2024,37(2):190-195.

[18]

何子毅,韩国伟,陈庆恺,等. 献血者混合标本与单标本核酸检测扩增效率及成本分析[J].中国输血杂志,2023,36(4):341-345.

[19]

HE Z Y,HAN G W,CHEN Q K,et al. Analysis of am-plification efficiency and cost of minipool and individual-donation nucleic acid testing in blood donors[J].Chin J Blood Transfusion,2023,36(4):341-345.

AI Summary AI Mindmap
PDF (1110KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉